GSK (NYSE:GSK) announced on Thursday that EU regulators approved two combination therapies involving its antibody drug conjugate, Blenrep, developed with Pfizer (PFE) and Kyowa Kirin (OTCPK:KYKOF ...

GSK’s anti-TIM monoclonal antibody (mAb) cobolimab has failed a Phase III trial in non-small cell lung cancer (NSCLC).

GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure.

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple myeloma. Read more here.